XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 28, 2016
USD ($)
Agreement
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues   $ 151,805 $ 32,811 $ 179,244 $ 54,113    
Contract liabilities   97,869   97,869   $ 111,055  
Collaboration and License agreements | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Sep. 28, 2016            
Number of agreements | Agreement 2            
Cash received as due under collaboration agreement $ 35,000            
License Collaboration And Stock Purchase Agreement | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock 21,500            
Olpasiran and ARO-AMG1 Agreement | Amgen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payments $ 30,000           $ 20,000
Revenues   0 $ 0 0 $ 0    
Contract liabilities   0   0      
Contract assets   0   0      
Olpasiran Agreement | Amgen | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Additional remaining development regulatory and sales milestones payments   $ 400,000   $ 400,000